title: Active and passive liver microvascular responses from angiotensin, endothelin, norepinephrine, and vasopressin.
abstract: Vasoconstrictor agents may induce a decrease in hepatic vascular volume passively, by decreasing distending pressure, or actively, by stimulating contractile elements of capacitance vessels. Hepatic venular resistance was estimated in anesthetized rabbits from hepatic venular pressure (P(mu hv); by servo-null micropipette), inferior vena cava pressure, and total hepatic blood flow (F(hv); by ultrasound flow probe). Changes in liver volume were estimated from measures of liver lobe thickness. Angiotensin (ANG) II, endothelin (ET)-1, norepinephrine (NE), and vasopressin (VP) were infused into the portal vein at a constant rate for 5 min. We conclude that ANG II and NE induced active constriction of hepatic capacitance vessels, because the liver lobe thickness decreased significantly even though P(mu hv) and portal venous distending pressure (P(pv)) increased. All four agents increased splanchnic and hepatic venous resistances in similar proportions. With VP, P(mu hv) and P(pv) decreased, but with ET-1, P(mu hv) and P(pv) increased. However, lobe thickness was not significantly changed by either drug during the infusion compared with the 2-min control period. Thus VP and ET-1 have only minor effects on hepatic capacitance vessels. ET-1, at 0.04 microg. min(-1). kg body wt(-1), caused an increase in systemic arterial blood pressure, but erythrocyte movement through the sinusoids in some animals stopped.
authors.affiliation: Department of Physiology, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA. crothe@iupui.edu
authors.forename: C F
authors.initials: CF
authors.lastname: Rothe
authors.forename: R
authors.initials: R
authors.lastname: Maass-Moreno
mesh_terms: D000804:Angiotensin II / Q000008:administration & dosage / Q000378:metabolism*; D000818:Animals; D004305:Dose-Response Relationship, Drug; D019332:Endothelin-1 / Q000008:administration & dosage / Q000378:metabolism*; D005260:Female; D007262:Infusions, Intravenous; D008099:Liver / Q000098:blood supply* / Q000000981:diagnostic imaging / Q000187:drug effects / Q000378:metabolism*; D008102:Liver Circulation / Q000187:drug effects / Q000502:physiology; D008297:Male; D008833:Microcirculation / Q000000981:diagnostic imaging / Q000187:drug effects / Q000378:metabolism; D009638:Norepinephrine / Q000008:administration & dosage / Q000378:metabolism*; D011169:Portal Vein; D011817:Rabbits; D014463:Ultrasonography; D014655:Vascular Resistance / Q000187:drug effects / Q000502:physiology; D014667:Vasopressins / Q000008:administration & dosage / Q000378:metabolism*
chemical_list: D019332:Endothelin-1; D014667:Vasopressins; D000804:Angiotensin II; D009638:Norepinephrine